1324 GMT - AstraZeneca's higher spending on research and development is a positive and crucial for it to build out its pipeline, UBS analysts say in a note. The British pharma giant generated higher-than-expected collaboration income, which it reinvested in R&D spending that grew 23% in the fourth quarter, the analysts say. "This is in line with UBS thesis that Astra Zeneca needs to increase R&D spend to prosecute the rich pipeline," UBS says. This year is key for the drugmaker, with seven expected late-stage trial results due, they say. Shares are up 5.8% at 117.70 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 06, 2025 08:24 ET (13:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。